Background Little is known about the epidemiology of eczema in adults. The goal of this
study was to determine the prevalence of and associations with adult eczema in the United …

Atopic dermatitis comorbidities extend well beyond the march to allergic conditions (food
allergy, asthma, allergic rhinitis, allergic conjunctivitis, and eosinophilic esophagitis), …

Background Dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha,
inhibits signaling of interleukin-4 and interleukin-13, type 2 cytokines that may be important …

AD is a chronic inflammatory skin disease affecting both children and adults. AD is associated
with a substantial public health burden secondary to high prevalence in many regions and …

Objective Atopic dermatitis (AD) is a chronic pruritic inflammatory skin disease with substantial
patient and population burdens. A number of comorbid health problems occur in patients …

Background Previous studies found conflicting results about whether atopic dermatitis (AD)
is associated with overweight/obesity. Objective We sought to examine the relationship …

Importance Abrocitinib, an oral, once-daily Janus kinase 1 selective inhibitor, was effective
and well tolerated in a phase 3 monotherapy trial of patients with moderate-to-severe atopic …

Background Lebrikizumab, a high-affinity IgG4 monoclonal antibody targeting interleukin-13,
prevents the formation of the interleukin-4Rα–interleukin-13Rα1 heterodimer receptor …

Background The patient burden and quality of life (QOL) impact of atopic dermatitis (AD) in
the United States population is not well established. Objective To elucidate the patient burden …

Background Nemolizumab targets the IL-31 receptor α subunit involved in atopic dermatitis (AD)
pathogenesis. Objective We sought to evaluate a new dosing strategy of nemolizumab …